Bionano Genomics vs Omniab
Bionano Genomics is the larger business, with $28.5m of revenue in fiscal 2025 against $18.7m for Omniab (1.5 times as much). Bionano Genomics grew faster (-7.4% against -29.3%). Bionano Genomics kept more of each dollar of sales as profit: a net margin of -92.6% against -347.0%. Bionano Genomics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bionano GenomicsBNGO, 2025 | OmniabOABI, 2025 |
|---|---|---|
| Revenue | $28.5m | $18.7m |
| Revenue growth | -7.4% | -29.3% |
| Net income | −$26.4m | −$64.8m |
| Operating margin | -116.9% | -369.5% |
| Net margin | -92.6% | -347.0% |
| Return on equity | -66.2% | -23.4% |
| Free cash flow | −$16.3m | −$37.0m |
| Cash | $3.0m | $25.5m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 97 | 89 |
| Market value | $14.1m | $736m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | — |
| Insider trades, 12 months | 2 buys, 0 sales | 2 buys, 12 sales |